It’s a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators’ hands.
{iframe}https://www.bizjournals.com/washington/news/2019/09/03/5-things-to-know-ahead-of-viela-bio-s-planned-150m.html{/iframe}